Drug Target Review2024-12-26T08:00:03
Learn how the University at Buffalo is pioneering safer, more effective ADC therapies.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-18T11:12:00Z
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, Drug Target Review
2026-11-17T09:31:00Z
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2025-03-19T15:00:00
Sponsored by Eurofins DiscoverX
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2026-07-10T06:15:00
Contributor Professor Donald E Ingber, Drug Target Review
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2025-08-05T13:42:00
Sponsored by ICON plc., Drug Target Review
Site powered by Webvision Cloud